High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Experimentally high dose of hyperoncotic human serum albumin improve neurological recovery
after head injury reduce cerebral edema and normalize apparent diffusion coefficient of water
after ischemia reperfusion. The main hypothesis is that early administration of hyperoncotic
serum albumin is able to reduce intracranial pressure for several days after severe head
injury and thus reduce mortality and morbidity.